Arcus Biosciences, Inc. RCUS
Arcus Biosciences, Inc. (NYSE: RCUS) is an oncology drug developer. Its lead program, casdatifan, is in Phase 3 for clear cell renal cell carcinoma (ccRCC). Its next catalyst on record is casdatifan: PEAK-1 Phase 3 registrational study ongoing (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: casdatifan — PEAK-1 Phase 3 registrational study ongoing (date not stated). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| casdatifan | ccRCC | small molecule | Phase 3 |
| quemliclustat | cancer (unspecified) | small molecule | Phase 3 |
| domvanalimab | Stage III unresectable NSCLC | antibody | Phase 3 |
| zimberelimab | ccRCC | antibody | Phase 2 |
| etrumadenant | cancer (unspecified) | small molecule | Phase 2 |
| AB598 | cancer/immunology | antibody | Phase 1 |
| AB801 | cancer/immunology | small molecule | Phase 1 |
| AB102 | immunology/inflammation | small molecule | Phase 1 |
| TNF small-molecule inhibitor | immunology/inflammation | small molecule | Pre-clinical |
Recent results and decisions
- Nov 4, 2026positive Casdatifan plus zimberelimab in first-line ccRCC showed 86% PFS at 6 months, 69% at 12 months, 50% cORR and 6.7% primary progression rate, exceeding benchmarks.
The combination demonstrated landmark PFS of 86% at 6 months and 69% at 12 months, a 50% confirmed objective response rate (cORR) and a 6.7% rate of primary progression.
Filing - started Arcus initiated a first-in-human healthy volunteer study for AB102 (oral MRGPRX2 antagonist) in August 2026.
AB102 (oral, MRGPRX2 antagonist): Arcus initiated a first-in-human healthy volunteer study in August 2026.
Filing - Dec 12, 2025missed Phase 3 STAR-221 discontinued for futility: at pre-specified OS interim analysis, dom+zim+chemo did not improve OS vs nivolumab plus chemotherapy.
At the interim analysis, the domvanalimab-based combination did not improve OS relative to nivolumab plus chemotherapy.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.